Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMNZYWR)

Drug Name

1-(3,3-Dimethyl-2-oxo-butyl)-1H-indole-2,3-dione Drug Info

Synonyms

1-(3,3-dimethyl-2-oxobutyl)-1H-indole-2,3-dione; 1-(3,3-dimethyl-2-oxobutyl)indole-2,3-dione; 214417-82-0; CHEMBL82686; AC1MU297; CTK7F3764; MolPort-003-013-041; ZINC3037941; ALBB-006420; STK506481; AKOS001570268; MCULE-7778783398; CCG-198354; TR-059060; SR-01000550574; 1-(2-Oxo-3,3-dimethylbutyl)-2,3-indolinedione

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 3659236
TTD Drug ID: DMNZYWR

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Neutrophil elastase (NE)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sivelestat sodium hydrate	DMOSJD0	Acute lung injury	NB32.3	Phase 4	[2]
Epigallocatechin gallate	DMCGWBJ	Hepatic fibrosis	DB93.0	Phase 3	[3]
Sivelestat	DM6BZCV	Crohn disease	DD70	Phase 3	[4]
Tiprelestat	DM1SB94	Myocardial infarction	BA41-BA43	Phase 2	[5]
AZD9668	DMB87M3	Bronchiectasis	CA24	Phase 2	[6]
L-694,458	DMA0DSJ	Cystic fibrosis	CA25	Phase 2	[7]
BAY 85-8501	DMCPUKG	Bronchiectasis	CA24	Phase 2	[8]
DX-890	DMBFZET	Acute lung injury	NB32.3	Phase 2	[2]
POL-6014	DM9B68S	Cystic fibrosis	CA25	Phase 1	[9]
AZD-9819	DMWYHXG	Chronic obstructive pulmonary disease	CA22	Phase 1	[10]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Targeting Plasminogen (PLG)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ranolazine	DM0C9IL	Acute coronary syndrome	BA41	Approved	[11]
Aminocaproic Acid	DMFGND4	Bleeding disorder	GA20-GA21	Approved	[12]
Streptokinase	DM5JQ0D	Pulmonary embolism	BB00	Approved	[13]
Tranexamic Acid	DMFI8A7	Excessive bleeding	GA30.02	Approved	[14]
Alteplase	DMRJ3YX	Acute myocardial infarction	BA41	Approved	[15]
Tenecteplase	DMJYN25	Acute myocardial infarction	BA41	Approved	[15]
Anistreplase	DM6Q4B0	Acute coronary syndrome	BA41	Approved	[16]
Reteplase	DML0D1P	Heart attack	BA41	Approved	[17]
MELAGATRAN	DM4W8RE	N. A.	N. A.	Phase 3	[18]
Desmoteplase	DMDLU4Z	Ischemic stroke	8B11.5Z	Phase 3	[19]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Neutrophil elastase (NE)	TTPLTSQ	ELNE_HUMAN	Inhibitor	[1]
Plasminogen (PLG)	TTP86E2	PLMN_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Parallel synthesis of isatin-based serine protease inhibitors. Bioorg Med Chem Lett. 2000 Nov 20;10(22):2501-4.
2	Emerging therapies for treatment of acute lung injury and acute respiratory distress syndrome. Expert Opin Emerg Drugs. 2007 Sep;12(3):461-77.
3	Evaluation of human neutrophil elastase inhibitory effect of iridoid glycosides from Hedyotis diffusa. Bioorg Med Chem Lett. 2010 Jan 15;20(2):513-5.
4	Neutrophil elastase inhibitor (sivelestat) reduces the levels of inflammatory mediators by inhibiting NF-kB. Inflamm Res. 2009 Apr;58(4):198-203.
5	Company report (Proteo Biotech AG)
6	Clinical pipeline report, company report or official report of AstraZeneca (2009).
7	Neutrophil elastase inhibitors as treatment for COPD. Expert Opin Investig Drugs. 2002 Jul;11(7):965-80.
8	Freezing the Bioactive Conformation to Boost Potency: The Identification of BAY 5-8501, a Selective and Potent Inhibitor of Human Neutrophil Elastase for Pulmonary Diseases. ChemMedChem. 2015 Jul;10(7):1163-73.
9	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2358).
10	Lipid Peroxide-Mediated Oxidative Rearrangement of the Pyrazinone Carboxamide Core of Neutrophil Elastase Inhibitor AZD9819 in Blood Plasma Samples. Drug Metab Dispos. 2015 Oct;43(10):1441-9.
11	Tranexamic acid in trauma: how should we use it. J Trauma Acute Care Surg. 2013 Jun;74(6):1575-86.
12	The blockage of the high-affinity lysine binding sites of plasminogen by EACA significantly inhibits prourokinase-induced plasminogen activation. Biochim Biophys Acta. 2002 Apr 29;1596(2):182-92.
13	Acute anuric renal failure with streptokinase therapy in a patient with acute venous thromboembolic disease and the review of renal side effects of streptokinase. Tuberk Toraks. 2008;56(4):456-61.
14	Evaluation of aprotinin and tranexamic acid in different in vitro and in vivo models of fibrinolysis, coagulation and thrombus formation. J Thromb Haemost. 2007 Oct;5(10):2113-8.
15	Thrombolytic therapies: the current state of affairs. J Endovasc Ther. 2005 Apr;12(2):224-32.
16	Evaluation of thrombolytic agents. Drugs. 1997;54 Suppl 3:11-6; discussion 16-7.
17	Fibrin binding and the regulation of plasminogen activators during thrombolytic therapy. Cardiovasc Hematol Agents Med Chem. 2008 Jul;6(3):212-23.
18	Orally active thrombin inhibitors. Part 1: optimization of the P1-moiety. Bioorg Med Chem Lett. 2006 May 15;16(10):2641-7.
19	Vampire bat salivary plasminogen activator (desmoteplase): a unique fibrinolytic enzyme that does not promote neurodegeneration. Stroke. 2003 Feb;34(2):537-43.